Send to

Choose Destination
See comment in PubMed Commons below
J Nucl Med. 2016 Sep;57(9):1388-95. doi: 10.2967/jnumed.115.166850. Epub 2016 Apr 21.

First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430.

Author information

  • 1Department of Radiology and Biomedical Imaging, PET Center, Yale School of Medicine, New Haven, Connecticut; and
  • 2Pfizer Worldwide Research and Development, Cambridge, Massachusetts.
  • 3Department of Radiology and Biomedical Imaging, PET Center, Yale School of Medicine, New Haven, Connecticut; and.


This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand (18)F-PF-05270430. The primary goals were to determine the appropriate tracer kinetic model to quantify brain uptake and to examine the within-subject test-retest variability.


In advance of human studies, radiation dosimetry was determined in nonhuman primates. Six healthy male subjects participated in a test-retest protocol with dynamic scans and metabolite-corrected input functions. Nine brain regions of interest were studied, including the striatum, white matter, neocortical regions, and cerebellum. Multiple modeling methods were applied to calculate volume of distribution (VT) and binding potentials relative to the nondisplaceable tracer in tissue (BPND), concentration of tracer in plasma (BPP), and free tracer in tissue (BPF). The cerebellum was selected as a reference region to calculate binding potentials.


The dosimetry study provided an effective dose of less than 0.30 mSv/MBq, with the gallbladder as the critical organ; the human target dose was 185 MBq. There were no adverse events or clinically detectable pharmacologic effects reported. Tracer uptake was highest in the striatum, followed by neocortical regions and white matter, and lowest in the cerebellum. Regional time-activity curves were well fit by multilinear analysis-1, and a 70-min scan duration was sufficient to quantify VT and the binding potentials. BPND, with mean values ranging from 0.3 to 0.8, showed the best intrasubject and intersubject variability and reliability. Test-retest variability in the whole brain (excluding the cerebellum) of VT, BPND, and BPP were 8%, 16%, and 17%, respectively.


(18)F-PF-05270430 shows promise as a PDE2A PET ligand, albeit with low binding potential values.


brain imaging; dosimetry; phosphodiesterase 2A; positron emission tomography; test-retest reproducibility

[PubMed - in process]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center